Fingerprint
Dive into the research topics of 'Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I/II study of the novel proteasome inhibitor delanzomib (CEP-18770) for relapsed and refractory multiple myeloma
Dan T. Vogl, Thomas G. Martin, Ravi Vij, Parameswaran Hari, Joseph R. Mikhael, David Siegel, Ka Lung Wu, Michel Delforge, Cristina Gasparetto
Research output: Contribution to journal › Article › peer-review
30
Scopus
citations